Paratek Pharmaceuticals (PRTK) Given New $22.00 Price Target at HC Wainwright

Paratek Pharmaceuticals (NASDAQ:PRTK) had its price objective reduced by HC Wainwright from $55.00 to $22.00 in a research note released on Friday morning. HC Wainwright currently has a buy rating on the specialty pharmaceutical company’s stock.

Several other research analysts also recently weighed in on the company. ValuEngine upgraded Paratek Pharmaceuticals from a strong sell rating to a sell rating in a research note on Tuesday, October 2nd. Bank of America started coverage on Paratek Pharmaceuticals in a research note on Monday, August 27th. They set a neutral rating and a $13.00 target price on the stock. Cantor Fitzgerald restated a buy rating and set a $50.00 target price on shares of Paratek Pharmaceuticals in a research note on Thursday, August 2nd. Wedbush set a $20.00 target price on Paratek Pharmaceuticals and gave the stock a buy rating in a research note on Thursday, August 9th. Finally, Guggenheim set a $26.00 target price on Paratek Pharmaceuticals and gave the stock a buy rating in a research note on Wednesday, October 3rd. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average price target of $25.57.

Shares of PRTK stock opened at $7.22 on Friday. Paratek Pharmaceuticals has a 1-year low of $6.27 and a 1-year high of $20.90. The company has a current ratio of 11.39, a quick ratio of 11.39 and a debt-to-equity ratio of 3.97. The firm has a market cap of $235.27 million, a P/E ratio of -2.19 and a beta of 0.74.

Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.85) by ($0.16). Paratek Pharmaceuticals had a negative return on equity of 132.55% and a negative net margin of 2,155.03%. The business had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $5.89 million. On average, equities research analysts forecast that Paratek Pharmaceuticals will post -3.29 earnings per share for the current fiscal year.

In other Paratek Pharmaceuticals news, COO Evan Loh sold 8,861 shares of Paratek Pharmaceuticals stock in a transaction dated Wednesday, October 3rd. The stock was sold at an average price of $9.82, for a total transaction of $87,015.02. Following the completion of the sale, the chief operating officer now owns 235,286 shares of the company’s stock, valued at approximately $2,310,508.52. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Adam Woodrow sold 8,750 shares of Paratek Pharmaceuticals stock in a transaction dated Wednesday, October 3rd. The stock was sold at an average price of $9.82, for a total value of $85,925.00. Following the sale, the vice president now directly owns 112,917 shares of the company’s stock, valued at approximately $1,108,844.94. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 58,446 shares of company stock valued at $559,369. 6.20% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently modified their holdings of the business. National Asset Management Inc. acquired a new position in shares of Paratek Pharmaceuticals in the 3rd quarter valued at about $117,000. Balter Liquid Alternatives LLC acquired a new position in shares of Paratek Pharmaceuticals in the 2nd quarter valued at about $137,000. Metropolitan Life Insurance Co. NY lifted its holdings in shares of Paratek Pharmaceuticals by 81.4% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 14,760 shares of the specialty pharmaceutical company’s stock valued at $151,000 after buying an additional 6,625 shares during the period. Clear Harbor Asset Management LLC acquired a new position in shares of Paratek Pharmaceuticals in the 2nd quarter valued at about $154,000. Finally, MetLife Investment Advisors LLC lifted its holdings in shares of Paratek Pharmaceuticals by 57.1% in the 2nd quarter. MetLife Investment Advisors LLC now owns 16,222 shares of the specialty pharmaceutical company’s stock valued at $165,000 after buying an additional 5,895 shares during the period. 75.31% of the stock is owned by institutional investors.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.

Further Reading: How can you know how many shares are floating?

Analyst Recommendations for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply